-
Je něco špatně v tomto záznamu ?
Non-colorectal liver metastases: surgical treatment options
Vladislav Treska, Vaclav Liska, Tomas Skalicky, Alan Sutnar, Inka Treskova, Andrea Narsanska, Monika Vachtova,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS10240
MZ0
CEP - Centrální evidence projektů
NS9727
MZ0
CEP - Centrální evidence projektů
PubMed
22251545
DOI
10.5754/hge10292
Knihovny.cz E-zdroje
- MeSH
- adjuvantní chemoterapie MeSH
- analýza přežití MeSH
- časové faktory MeSH
- dospělí MeSH
- hepatektomie škodlivé účinky mortalita MeSH
- katetrizační ablace škodlivé účinky mortalita MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázektomie škodlivé účinky mortalita MeSH
- míra přežití MeSH
- nádory jater mortalita sekundární chirurgie MeSH
- neoadjuvantní terapie MeSH
- přežívající statistika a číselné údaje MeSH
- prospektivní studie MeSH
- senioři MeSH
- terapeutická embolizace MeSH
- výběr pacientů MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND/AIMS: Due to different biological characteristics of non-colorectal liver metastasizes (NCLM), surgical treatment, especially it´s long term results, is a topic of discussion. The aim of the study was to evaluate the single center experience with surgical treatment of NCLM. METHODOLOGY: Seventy two patients were prospectively included. The average length of time after the primary surgery was 3.9 years (0-8.5 years). RFA prevailed -50 patients (69.4%), resection presenting 30.6%. Preoperative chemotherapeutical downstaging or portal vein embolization was performed on 12 patients (16.7%). Resectable or radiofrequency ablation (RFA) treatable extrahepatic metastasizes were removed in 26 patients (36.1%). RESULTS: One, three and five years patient survival after the liver resection or RFA was 88.6, 72.5 and 36.9%. The best survival rate was in patients with carcinoid (5 years-100%), breast cancer (5 years-33.8%), renal carcinoma (3 years-44.4% ) and gynecological tumors metastasizes (2 years-72.9%). With regards to long-term survival of patients, we did not find any statistically significant difference between RFA and resection. Patients with extrahepatic metastasizes had worse prognosis (p<0.01). CONCLUSIONS: Liver resection and RFA in NCLM have an unambiguous place in multi-modal curative strategy. The decision for surgical treatment of patients suffering from NCLM, is strictly individual with the aim of achieving qualitative long-term survival.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12024112
- 003
- CZ-PrNML
- 005
- 20140901162127.0
- 007
- ta
- 008
- 120815s2012 gr f 000 0eng||
- 009
- AR
- 024 7_
- $a 10.5754/hge10292 $2 doi
- 035 __
- $a (PubMed)22251545
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Treska, Vladislav $u Department of Surgery, School of Medicine, Plxen, Czech Republic. treska@fnplzen.cz
- 245 10
- $a Non-colorectal liver metastases: surgical treatment options / $c Vladislav Treska, Vaclav Liska, Tomas Skalicky, Alan Sutnar, Inka Treskova, Andrea Narsanska, Monika Vachtova,
- 520 9_
- $a BACKGROUND/AIMS: Due to different biological characteristics of non-colorectal liver metastasizes (NCLM), surgical treatment, especially it´s long term results, is a topic of discussion. The aim of the study was to evaluate the single center experience with surgical treatment of NCLM. METHODOLOGY: Seventy two patients were prospectively included. The average length of time after the primary surgery was 3.9 years (0-8.5 years). RFA prevailed -50 patients (69.4%), resection presenting 30.6%. Preoperative chemotherapeutical downstaging or portal vein embolization was performed on 12 patients (16.7%). Resectable or radiofrequency ablation (RFA) treatable extrahepatic metastasizes were removed in 26 patients (36.1%). RESULTS: One, three and five years patient survival after the liver resection or RFA was 88.6, 72.5 and 36.9%. The best survival rate was in patients with carcinoid (5 years-100%), breast cancer (5 years-33.8%), renal carcinoma (3 years-44.4% ) and gynecological tumors metastasizes (2 years-72.9%). With regards to long-term survival of patients, we did not find any statistically significant difference between RFA and resection. Patients with extrahepatic metastasizes had worse prognosis (p<0.01). CONCLUSIONS: Liver resection and RFA in NCLM have an unambiguous place in multi-modal curative strategy. The decision for surgical treatment of patients suffering from NCLM, is strictly individual with the aim of achieving qualitative long-term survival.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a katetrizační ablace $x škodlivé účinky $x mortalita $7 D017115
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a terapeutická embolizace $7 D004621
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hepatektomie $x škodlivé účinky $x mortalita $7 D006498
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory jater $x mortalita $x sekundární $x chirurgie $7 D008113
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metastázektomie $x škodlivé účinky $x mortalita $7 D059146
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a výběr pacientů $7 D018579
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a přežívající $x statistika a číselné údaje $7 D017741
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Liska, Vaclav $u Department of Surgery, School of Medicine, Plxen, Czech Republic
- 700 1_
- $a Skalicky, Tomas $u Department of Surgery, School of Medicine, Plxen, Czech Republic
- 700 1_
- $a Sutnar, Alan $u Department of Surgery, School of Medicine, Plxen, Czech Republic
- 700 1_
- $a Treskova, Inka $u Department of Surgery, School of Medicine, Plxen, Czech Republic
- 700 1_
- $a Narsanska, Andrea $u Department of Surgery, School of Medicine, Plxen, Czech Republic
- 700 1_
- $a Vachtova, Monika $u Department of Surgery, School of Medicine, Plxen, Czech Republic
- 773 0_
- $w MED00002025 $t Hepato-gastroenterology $x 0172-6390 $g Roč. 59, č. 113 (2012), s. 245-248
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22251545 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120815 $b ABA008
- 991 __
- $a 20140901162517 $b ABA008
- 999 __
- $a ok $b bmc $g 946260 $s 781440
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 59 $c 113 $d 245-248 $i 0172-6390 $m Hepato-gastroenterology $n Hepatogastroenterology $x MED00002025
- GRA __
- $a NS10240 $p MZ0
- GRA __
- $a NS9727 $p MZ0
- LZP __
- $a Pubmed-20120815/12/02